diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5645diaendo-5645Research ArticleСтатьиArticlesПрепараты сульфонилмочевины в современной стратегии лечения сахарного диабета 2 типSulfonylureas in the modern strategy of therapy of type 2 diabetesНедосуговаЛюдмила ВикторовнаNedosugovaLyudmila Viktorovnaprofmila@rambler.ruГОУ ВПО Первый московский государственный медицинский университет им. И. М. Сеченова, МоскваI.M.Sechenov First Moscow State Medical University, Moscow201115062011142№2 (2011)99109Copyright © Недосугова Л.В., 20112011Недосугова Л.В.Nedosugova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5645

Сахарный диабет 2 типа (СД2) - хроническое, прогрессирующее заболевание, характеризующееся инсулинорезистентностью и недо-статочной секрецией инсулина для преодоления барьера инсулинорезистентности, прогрессирующей с течением времени в результатеглюкозотоксичности и апоптоза ?-клеток. Современная стратегия сахароснижающей терапии расценивает комбинацию метформинас препаратами сульфонилмочевины (ПСМ) как эффективную, позволяющую одновременно воздействовать на основные звенья патоге-неза, но и не лишенной риска развития побочных эффектов, таких как гипогликемии, увеличение веса, негативные кардио-васкулярныеэффекты. В этом отношении Амарил - ПСМ третьего поколения - отвечает требованиям эффективности и безопасности, предъяв-ляемым к комбинированной сахароснижающей терапии, за счет своей высокой аффинности к особой субъединице рецептора сульфонил-мочевины SUR 1 на ?-клетке и кратковременности стимулирующего влияния на секрецию инсулина - с одной стороны, а также за счетуникального, не связанного с SUR экстрапанкреатического механизма действия - с другой. Доказанная эффективность и безопасностьпрепарата в целом ряде рандомизированных исследований позволяет рекомендовать его для всех современных комбинаций сахароснижающих препаратов, включая и самые современные средства инкретинового ряда, с минимальным риском гипогликемических состояний,отсутствием увеличения веса, положительным эффектом на сердечно-сосудистую систему и прогрессирование атеросклероза.

Type 2 diabetes mellitus (DM2) is a chronic progressing disease associated with insulin resistance and impaired insulin secretion insufficient toovercome insulin resistance that deteriorates as a result of glucose toxicity and beta-cell apoptosis. Combination of metformin and sulfonylureas (SU) iscurrently regarded as an effective strategy of hypoglycemic therapy having effect not only on the main stages of pathogenesis but also on t dangerousrisk factors leading to adverse events (hypoglycemia, body weight increment, cardiovascular disorders). Amaryl, SU of the 3d generation, meets allcriteria of safety and efficacy for combined hypoglycemic therapy due to its high affinity to a specific subunit of SU receptors-1 on beta-cells coupled toshort-term stimulating action on insulin secretion. Moreover, it has a unique SU-unrelated extrapancreatic mechanism of action. The efficacy andsafety of Amaryl was confirmed in a number of clinical studies which gives reason to recommend it for inclusion in any modern hypoglycemic therapywith a minimal risk of hypoglycemia, lack of weight increment, positive effect on the cardiovascular system and progress of atherosclerosis

терапиясахарный диабет 2 типаинсулинорезистентностьсекреция инсулинарецептор сульфонилмочевиныКАТФ-каналыSURtherapytype 2 diabetes mellitusinsulin resistanceinsulin secretionsulphonylurea receptorKatp channelsReferencesWorld Health Organisation. The World Health Report 1998. Life in 21st Century - a Vision for ALL // Geneva: World Health Organisation, 1998.World Health Organisation. The World Health Report 1998. Life in 21st Century - a Vision for ALL // Geneva: World Health Organisation, 1998.Hsueh W.A., Law R.E. Cardiovascular risk continuum: Implications of insulin resistance and diabetes //Am. J. Med. - 1998. - № 105. - Р. 4S-14SHsueh W.A., Law R.E. Cardiovascular risk continuum: Implications of insulin resistance and diabetes //Am. J. Med. - 1998. - № 105. - Р. 4S-14SO'Brien R.C., Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro // Methabolism. - 1997. - № 46(Suppl 1). - Р. 22-25.O'Brien R.C., Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro // Methabolism. - 1997. - № 46(Suppl 1). - Р. 22-25.Доборджгинидзе Л.М., Грацианский Н.А. Роль статинов в коррекции диабетической дислипидемии // Сах. диабет. - 2001. - № 2. - Р. 41-47.Доборджгинидзе Л.М., Грацианский Н.А. Роль статинов в коррекции диабетической дислипидемии // Сах. диабет. - 2001. - № 2. - Р. 41-47.Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years // Diabetes Care. - 1999. - № 22. - Р. 233-240.Coutinho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years // Diabetes Care. - 1999. - № 22. - Р. 233-240.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.Ohkubo Y., Kishikawa H., Araki E., Takao M., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study // Diabetes Res Clin. Pract. - 1995. - № 28. - Р. 103-117.Ohkubo Y., Kishikawa H., Araki E., Takao M., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study // Diabetes Res Clin. Pract. - 1995. - № 28. - Р. 103-117.Kahn S.E., Zinman B., Lachin J.M. (A Diabetes Outcome Progression Trial [ADOPT] Study Group). Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. - 2008. - № 31. - Р. 845-851.Kahn S.E., Zinman B., Lachin J.M. (A Diabetes Outcome Progression Trial [ADOPT] Study Group). Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. - 2008. - № 31. - Р. 845-851.Patel A., MacMahon S., Chalmers J. (ADVANCE Collaborative Group).Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Patel A., MacMahon S., Chalmers J. (ADVANCE Collaborative Group).Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2560-2572.Wilcox R., Kupfer S., Erdmann E. (PROactive Study Investigators). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) // Am. Heart. J. - 2008. - № 155. - Р. 712-717.Wilcox R., Kupfer S., Erdmann E. (PROactive Study Investigators). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) // Am. Heart. J. - 2008. - № 155. - Р. 712-717.Nathan D.M., Cleary P.A., Backlund J.Y. (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [DCCT/ EDIC] Study Research Group). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. - 2005. - № 353. - Р. 2643-2653Nathan D.M., Cleary P.A., Backlund J.Y. (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [DCCT/ EDIC] Study Research Group). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. - 2005. - № 353. - Р. 2643-2653Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes // N. Engl. J. Med. - 2008. - № 359. - Р. 1577-1589.Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes // N. Engl. J. Med. - 2008. - № 359. - Р. 1577-1589.Gaede P., Valentine W.J., Palmer A.J. Costeffectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study // Diabetes Care. - 2008. - № 31. - Р. 1510-1515.Gaede P., Valentine W.J., Palmer A.J. Costeffectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study // Diabetes Care. - 2008. - № 31. - Р. 1510-1515.Home P.D., Pocock S.J., Beck-Nielsen H. (RECORD Study Team). Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, openlabel trial // Lancet. - 2009. - № 373. - Р. 2125-2135.Home P.D., Pocock S.J., Beck-Nielsen H. (RECORD Study Team). Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, openlabel trial // Lancet. - 2009. - № 373. - Р. 2125-2135.Miller M.E., Byington R.P., Goff DC Jr. (Action to Control Cardiovascular Risk in Diabetes Study Group). Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Miller M.E., Byington R.P., Goff DC Jr. (Action to Control Cardiovascular Risk in Diabetes Study Group). Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - № 358. - Р. 2545-2559.Duckworth W., Abraira C., Moritz T. (VADT Investigators). Glucose control and vascular complications in veterans with type 2 diabetes // N.Duckworth W., Abraira C., Moritz T. (VADT Investigators). Glucose control and vascular complications in veterans with type 2 diabetes // N.Engl. J. Med. - 2009. - № 360. - Р. 129-139.Engl. J. Med. - 2009. - № 360. - Р. 129-139.Nathan D.M. Medical Management of Hyperglycemia in 1Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2009. - № 32. - Р. 1-11.Nathan D.M. Medical Management of Hyperglycemia in 1Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2009. - № 32. - Р. 1-11.DeFronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes // Diabetes Rev. - 1997. - № 5. - Р. 177-269DeFronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes // Diabetes Rev. - 1997. - № 5. - Р. 177-269Kahn C.R., Vicent D., Doria A. Genetics of non-insulin-dependent (type‑II) diabetes mellitus // Annu. Rev. Med. - 1996. - № 47. - Р. 509-531Kahn C.R., Vicent D., Doria A. Genetics of non-insulin-dependent (type‑II) diabetes mellitus // Annu. Rev. Med. - 1996. - № 47. - Р. 509-531Kahn C.R. Insulin action, diabetogenes, and the cause of type II diabetes // Diabetes. - 1994. - № 43. - Р. 1066-1084Kahn C.R. Insulin action, diabetogenes, and the cause of type II diabetes // Diabetes. - 1994. - № 43. - Р. 1066-1084UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update // Ann Intern Med. - 2002. - № 137. - Р. 25-33Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update // Ann Intern Med. - 2002. - № 137. - Р. 25-33Riccio A., Del Prato S., Vigili de Kreutzenberg S., Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin // Diabete Metab. - 1991. - № 17. - Р. 180-184Riccio A., Del Prato S., Vigili de Kreutzenberg S., Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin // Diabete Metab. - 1991. - № 17. - Р. 180-184Perriello G., Misericordia P., Volpi E. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production // Diabetes. - 1994. - № 43. - Р. 920-928Perriello G., Misericordia P., Volpi E. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production // Diabetes. - 1994. - № 43. - Р. 920-928Radziuk J., Zhang Z., Wiernsperger N., Pye S. Metformin and its liver targets in the treatment of type 2 diabetes // Curr Drug Targets Immune Endocrin Metabol Disord. - 2003. - № 3. - Р. 151-69.Radziuk J., Zhang Z., Wiernsperger N., Pye S. Metformin and its liver targets in the treatment of type 2 diabetes // Curr Drug Targets Immune Endocrin Metabol Disord. - 2003. - № 3. - Р. 151-69.Wollen N., Bailey C.J. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin // Biochem Pharmac. - 1988. - № 37. - Р. 4353-8Wollen N., Bailey C.J. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin // Biochem Pharmac. - 1988. - № 37. - Р. 4353-8Ferner R.E., Rawlins M.D., Alberti K.G. MM. Impaired B-cell responses improve when fasting blood glucose concentrate is reduced in noninsulindependent diabetes // Quat. J. Med. - 1988. - № 250. - Р. 137-46.Ferner R.E., Rawlins M.D., Alberti K.G. MM. Impaired B-cell responses improve when fasting blood glucose concentrate is reduced in noninsulindependent diabetes // Quat. J. Med. - 1988. - № 250. - Р. 137-46.AACE/ACE Consensus Statement. Glycemic Control Algorithm // Endocr. Pract. - 2009. - № 15. - Р. 541-559.AACE/ACE Consensus Statement. Glycemic Control Algorithm // Endocr. Pract. - 2009. - № 15. - Р. 541-559.Schwartz S. et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of the two oral drugs // Diabetes Care. - 2003. - № 26. - Р. 2238-2243Schwartz S. et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of the two oral drugs // Diabetes Care. - 2003. - № 26. - Р. 2238-2243De Fronzo R.A., Godman A.M. And The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus // N. Engl. J. Med. - 1995. - № 333. - Р. 541-549.De Fronzo R.A., Godman A.M. And The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus // N. Engl. J. Med. - 1995. - № 333. - Р. 541-549.Hermann L.S., Schersten B., P-O Bitsen et al. Therapeutic comparison of metformin and sulphonylurea alone and in various combinations // Diabetes Care. - 1994. - № 17. - Р. 1100-1109.Hermann L.S., Schersten B., P-O Bitsen et al. Therapeutic comparison of metformin and sulphonylurea alone and in various combinations // Diabetes Care. - 1994. - № 17. - Р. 1100-1109.Tosi F., Muggeo M., Brun E. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study // Metabolism. - 2003. - № 7. - Р. 862-867.Tosi F., Muggeo M., Brun E. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study // Metabolism. - 2003. - № 7. - Р. 862-867.Hermann L.S., Schersten B., P-O Bitsen. Therapeutic comparison of metformin and sulphonylurea alone and in various combinations // Diabetes Care. - 1994. - № 17. - Р. 1100-1109.Hermann L.S., Schersten B., P-O Bitsen. Therapeutic comparison of metformin and sulphonylurea alone and in various combinations // Diabetes Care. - 1994. - № 17. - Р. 1100-1109.Yarnell J.W., Patterson C.C., Thomas H.F., Sweetnam P.M. Comparison of weight in middle age, weight at 18 years, and weight change between, in predicting subsequent 14 year mortality and coronary events: Caerphilly Prospective Study // J. Epidemiol Community Health. - 2000. - № 54. - Р. 344-348.Yarnell J.W., Patterson C.C., Thomas H.F., Sweetnam P.M. Comparison of weight in middle age, weight at 18 years, and weight change between, in predicting subsequent 14 year mortality and coronary events: Caerphilly Prospective Study // J. Epidemiol Community Health. - 2000. - № 54. - Р. 344-348.Rosengren A., Wedel H., Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study // Eur. Heart. J. - 1999. - № 20. - Р. 269-277.Rosengren A., Wedel H., Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study // Eur. Heart. J. - 1999. - № 20. - Р. 269-277.Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old // N Engl J Med. - 2006. - 355. - Р. 763-778.Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old // N Engl J Med. - 2006. - 355. - Р. 763-778.Ashcroft F.M., Gribble F.M. ATP-sensitive K_ channels and insulin secretion: their role in health and disease // Diabetologia. - 1999. - № 42. - Р. 903-919. 38. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl // Molecular Medicine. - 2000. - № 6. - Р. 907-933,Ashcroft F.M., Gribble F.M. ATP-sensitive K_ channels and insulin secretion: their role in health and disease // Diabetologia. - 1999. - № 42. - Р. 903-919. 38. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl // Molecular Medicine. - 2000. - № 6. - Р. 907-933,Holstein A., PlaschkeA., Egberts E.-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab. Res. Rev. - 2001. - № 17. - Р. 467-473.Holstein A., PlaschkeA., Egberts E.-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab. Res. Rev. - 2001. - № 17. - Р. 467-473.Langtry H.D., Balfour J.A. Glimepiride-a review of its pharmacological and clinical efficacyin the management of type 2 diabetes mellitus // Drugs. - 1998. - № 55. - Р. 563-584.Langtry H.D., Balfour J.A. Glimepiride-a review of its pharmacological and clinical efficacyin the management of type 2 diabetes mellitus // Drugs. - 1998. - № 55. - Р. 563-584.Draeger E. Clinical profile of glimepiride // Diabetes Res. Clin.Pract. - 1995. - № 28. - Р. S139-S146Draeger E. Clinical profile of glimepiride // Diabetes Res. Clin.Pract. - 1995. - № 28. - Р. S139-S146Lebovitz H.E. Oral hypoglycemic agents. In: Rifkin H., Porte D. (eds.) Ellenberg and Rifkin's // Diabetes mellitus. Theory and Practise Elsevier. - 1990. - Р. 554-574. 42. Müller G., Wied S., Wetekam E-M., Crecelius A., Unkelbach A., Pünter J. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade // Biochem. Pharmacol. - 1994. - № 48. - Р. 985-996.Lebovitz H.E. Oral hypoglycemic agents. In: Rifkin H., Porte D. (eds.) Ellenberg and Rifkin's // Diabetes mellitus. Theory and Practise Elsevier. - 1990. - Р. 554-574. 42. Müller G., Wied S., Wetekam E-M., Crecelius A., Unkelbach A., Pünter J. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade // Biochem. Pharmacol. - 1994. - № 48. - Р. 985-996.Davidson M.B., Molnar G., Furman A., Yamaguchi D. Glyburidestimulated glucosetransport in cultured muscle cells via protein kinase C-mediated pathway requiring new protein synthesis // Diabetes. - 1991. - № 40. - Р. 1531-1538.Davidson M.B., Molnar G., Furman A., Yamaguchi D. Glyburidestimulated glucosetransport in cultured muscle cells via protein kinase C-mediated pathway requiring new protein synthesis // Diabetes. - 1991. - № 40. - Р. 1531-1538.Rogers B.J., Standaert M.L., Pollet R.J. Direct effects of sulfonylurea agents on glucose transport BC3H-1 myocyte // Diabetes. - 1987. - № 36. - Р. 1292-1296.Rogers B.J., Standaert M.L., Pollet R.J. Direct effects of sulfonylurea agents on glucose transport BC3H-1 myocyte // Diabetes. - 1987. - № 36. - Р. 1292-1296.Bak J.F., Schmitz O., Sorensen N.S., Pedersen O. Post-receptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients // Diabetes. - 1989. - № 38. - Р. 1343-1350.Bak J.F., Schmitz O., Sorensen N.S., Pedersen O. Post-receptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients // Diabetes. - 1989. - № 38. - Р. 1343-1350.Altan N., ALtan V.M., Mikolay L., Larner J., Schwartz C.F.W. Insulin-like and insulin-enhancing effects of the sulfonylurea glyburide on rat adipose glycogen synthase // Diabetes. - 1985. - № 34. - Р. 281-286.Altan N., ALtan V.M., Mikolay L., Larner J., Schwartz C.F.W. Insulin-like and insulin-enhancing effects of the sulfonylurea glyburide on rat adipose glycogen synthase // Diabetes. - 1985. - № 34. - Р. 281-286.Pulido N., Casla A., Suarez A., Casanova B., Arrieta F.J., Rovira A. Sulphonylurea stimulates glucose uptake in rats through an ATPsensitive K+ channel dependent mechanism // Diabetologia. - 1996. - № 39. - Р. 22-27.Pulido N., Casla A., Suarez A., Casanova B., Arrieta F.J., Rovira A. Sulphonylurea stimulates glucose uptake in rats through an ATPsensitive K+ channel dependent mechanism // Diabetologia. - 1996. - № 39. - Р. 22-27.Nystrom F.H., Quon M.J. Insulin signalling:Metabolic pathways and mechanismsfor specificity // Cell. Signal. - 1999. - № 11. - Р. 563-574.Nystrom F.H., Quon M.J. Insulin signalling:Metabolic pathways and mechanismsfor specificity // Cell. Signal. - 1999. - № 11. - Р. 563-574.Takada Y., Takata Y., Iwanishi M. Effect of glimepiride (HOE490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse // Eur. J. Pharmacol. - 1996. - № 308. - Р. 205-210.Takada Y., Takata Y., Iwanishi M. Effect of glimepiride (HOE490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse // Eur. J. Pharmacol. - 1996. - № 308. - Р. 205-210.Volk A., Maerker E., Rett K., Häring H.U., Overkamp D. Glimepirideeffects on peripheral insulin sensitivity // Diabetologia. - 2000. - № 43 (supplement 1):A39 [abstract]).Volk A., Maerker E., Rett K., Häring H.U., Overkamp D. Glimepirideeffects on peripheral insulin sensitivity // Diabetologia. - 2000. - № 43 (supplement 1):A39 [abstract]).Koshiba K., Nomuro M., Nakaya Y., Susumu I. Efficacy of glimepiride on insulin resistance, adipocytokines and atherosclerosis // J Med. Invest. - 2006. - № 53. - Р. 87-94Koshiba K., Nomuro M., Nakaya Y., Susumu I. Efficacy of glimepiride on insulin resistance, adipocytokines and atherosclerosis // J Med. Invest. - 2006. - № 53. - Р. 87-94Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity // J. Biol Chem. - 2005. - № 280. - Р. 23653-23659.Fukuen S., Iwaki M., Yasui A., Makishima M., Matsuda M., Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity // J. Biol Chem. - 2005. - № 280. - Р. 23653-23659.Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake // Nature. - 2000. - № 404. - Р. 661-671.Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake // Nature. - 2000. - № 404. - Р. 661-671.Weitgasser R., Lechleitner M., Luger A., Klingler A. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study // Diabetes Research and Clinical Practice. - 2003. - № 61. - Р. 13-19.Weitgasser R., Lechleitner M., Luger A., Klingler A. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study // Diabetes Research and Clinical Practice. - 2003. - № 61. - Р. 13-19.Terzic A., Jahangir A., Kurachi Y. Cardiac ATP-sensitive K1 channels: regulation by intracellular nucleotides and potassium opening drugs // Am J Physiol. - 1995. - № 38. - Р. C525-45.Terzic A., Jahangir A., Kurachi Y. Cardiac ATP-sensitive K1 channels: regulation by intracellular nucleotides and potassium opening drugs // Am J Physiol. - 1995. - № 38. - Р. C525-45.Zhang H., Cook D. Antagonism of eicozanoid-induced contraction of rat aorta by sulphonylureas // Pharmacology. - 1994. - № 49. - Р. 183-193.Zhang H., Cook D. Antagonism of eicozanoid-induced contraction of rat aorta by sulphonylureas // Pharmacology. - 1994. - № 49. - Р. 183-193.Geisen K., Vegh A., Krause E. Cardiovascular effects of conventional sulphonylureas and glimepiride // Horm. Metab. Res. - 1996. - № 28. - Р. 496-507Geisen K., Vegh A., Krause E. Cardiovascular effects of conventional sulphonylureas and glimepiride // Horm. Metab. Res. - 1996. - № 28. - Р. 496-507Derosa G., Franzetti I., Gadaleta G., Ciccarelli L., Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin // Diabetes Nutr. Metab. - 2004. - № 17. - Р. 143-50Derosa G., Franzetti I., Gadaleta G., Ciccarelli L., Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin // Diabetes Nutr. Metab. - 2004. - № 17. - Р. 143-50Ueba H., Kuroki M., Hashimoto S., Umemoto T., Yasu T., Ishikawa S.E., Saito M., Kawakami M. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway // Atherosclerosis. - 2005. - № 183. - Р. 35-9.Ueba H., Kuroki M., Hashimoto S., Umemoto T., Yasu T., Ishikawa S.E., Saito M., Kawakami M. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway // Atherosclerosis. - 2005. - № 183. - Р. 35-9.Langtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus // Drugs. - 1998. - № 55. - Р. 563-84Langtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus // Drugs. - 1998. - № 55. - Р. 563-84Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS // Diabetes Metab. Res. Rev. - 2002. - № 18 Suppl 3. - Р. S32-5.Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS // Diabetes Metab. Res. Rev. - 2002. - № 18 Suppl 3. - Р. S32-5.Matsuki M., Matsuda M., Kohara K., Shimoda M., Kanda Y., Tawaramoto K., Shigetoh M., Kawasaki F., Kotani K., Kaku K. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once. - versus twice-daily dosing // Endocr J. - 2007. - № 54. - Р. 571-6.Matsuki M., Matsuda M., Kohara K., Shimoda M., Kanda Y., Tawaramoto K., Shigetoh M., Kawasaki F., Kotani K., Kaku K. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once. - versus twice-daily dosing // Endocr J. - 2007. - № 54. - Р. 571-6.Charpentier G., Fleury F., Kabir M. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients // Diabet. Med. - 2001. - № 18. - Р. 828-834.Charpentier G., Fleury F., Kabir M. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients // Diabet. Med. - 2001. - № 18. - Р. 828-834.Derosa G., Cicero A.F., D'Angelo A., Gaddi A., Ciccarelli L., Piccinni M.N., Salvadeo S.A., Pricolo F., Ferrari I., Gravina A., Ragonesi P.D. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial // Clin. Ther. - 2006. - № 28. - Р. 679-688.Derosa G., Cicero A.F., D'Angelo A., Gaddi A., Ciccarelli L., Piccinni M.N., Salvadeo S.A., Pricolo F., Ferrari I., Gravina A., Ragonesi P.D. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial // Clin. Ther. - 2006. - № 28. - Р. 679-688.Marre M., Shaw J., Brandle M., Wan Bebakar W., Kamaruddin N., Strand J., Zdravkovic M., Le-Thi T.D., Colagiuri S., on behalf of the LEAD-1 SU study group: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control comparedwith adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diabet Med. - 2009. - № 26(3) . - Р. 268-278.Marre M., Shaw J., Brandle M., Wan Bebakar W., Kamaruddin N., Strand J., Zdravkovic M., Le-Thi T.D., Colagiuri S., on behalf of the LEAD-1 SU study group: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control comparedwith adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diabet Med. - 2009. - № 26(3) . - Р. 268-278.Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin // Diabetes Obes. Metab. - 2007. - № 9(5). - Р. 733 45Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin // Diabetes Obes. Metab. - 2007. - № 9(5). - Р. 733 45Kabadi U.M., Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes // Diabetes Research and Clinical Practice. - 2006. - № 72. - Р. 265-270.Kabadi U.M., Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes // Diabetes Research and Clinical Practice. - 2006. - № 72. - Р. 265-270.

The authors declare that there are no conflicts of interest present.